Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab in HER2-low invasive breast cancer
NCT01275677Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2011
- Primary completion
- Jul 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 3 trial of trastuzumab in Invasive breast cancer (IBC), sponsored by National Cancer Institute. Started Feb 2011; status: completed.
02
Drugs
03
Conditions
Invasive breast cancer (IBC)
Beyond the preview
Go deeper on NCT01275677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01275677.